Drug · DIN 02520893
RINVOQ
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 28, 2021; first marketed October 28, 2021.
- Drug Identification Number (DIN)
- 02520893
- Company (DIN owner)
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet (Extended-Release)
- Route
- Oral
- Therapeutic class (ATC)
- Upadacitinib L04AF03
- Class
- Human
- Record last updated
- August 7, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| UPADACITINIB | 30 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 6, 2021: NOC 26803Supplement to a New Drug Submission (SNDS) · To extend the indication and the addition of a new strength
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “rinvoq”. A notice may cover another product or only some lots: read it to see what it covers.
- Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancerNovember 1, 2022 · Drugs · Labelling
- Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and MalignancyOctober 31, 2022 · Drugs · New safety information - Product safety
Other DINs named RINVOQ
- DIN 02495155 · Marketed
- DIN 02539721 · Marketed